These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32622691)

  • 61. [The use of direct oral anticoagulants (DOAC) in the treatment atrial fibrillation (AF) patients].
    Lehto M; Mustonen P; Tierala I
    Duodecim; 2014; 130(17):1709-17. PubMed ID: 25272782
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation.
    Giustozzi M; Agnelli G; Quattrocchi S; Acciarresi M; Alberti A; Caso V; Vedovati MC; Venti M; Paciaroni M
    Cerebrovasc Dis Extra; 2020; 10(2):44-49. PubMed ID: 32375143
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence.
    Benedetti G; Neccia M; Agati L
    Minerva Cardioangiol; 2018 Jun; 66(3):301-313. PubMed ID: 29125269
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of Oral Anticoagulants on Patients With Atrial Fibrillation Aged 90 Years and Older: Comparison Among Direct Oral Anticoagulant, Warfarin Anticoagulant, and Nonanticoagulation.
    Yamaji H; Higashiya S; Murakami T; Hina K; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):246-254. PubMed ID: 31498193
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Convenience and satisfaction in direct oral anticoagulant-treated patients with atrial fibrillation.
    Piersma-Wichers M; Elling T; de Vries-Bots AMB; Kooistra HAM; Meijer K
    Res Pract Thromb Haemost; 2021 Aug; 5(6):e12577. PubMed ID: 34430791
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Practices, beliefs, and attitudes of clinicians in prescribing direct oral anticoagulants for obese adults with atrial fibrillation: a qualitative study.
    Shaikh F; Wynne R; Castelino RL; Inglis SC; Davidson PM; Ferguson C
    Int J Clin Pharm; 2023 Aug; 45(4):962-969. PubMed ID: 37253952
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.
    Zoppellaro G; Granziera S; Padayattil Jose S; Denas G; Bracco A; Iliceto S; Pengo V
    Expert Opin Drug Saf; 2015 May; 14(5):683-95. PubMed ID: 25803739
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
    Alamneh EA; Chalmers L; Bereznicki LR
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
    [TBL] [Abstract][Full Text] [Related]  

  • 70. SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation.
    Kapoor A; Amroze A; Vakil F; Crawford S; Der J; Mathew J; Alper E; Yogaratnam D; Javed S; Elhag R; Lin A; Narayanan S; Bartlett D; Nagy A; Shagoury BK; Fischer MA; Mazor KM; Saczynski JS; Ashburner JM; Lopes R; McManus DD
    Circ Cardiovasc Qual Outcomes; 2020 Feb; 13(2):e005871. PubMed ID: 32063041
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Patient Adherence to Novel Oral Anticoagulants (NOACs) for the Treatment of Atrial Fibrillation and Occurrence of Associated Bleeding Events: A Systematic Review and Meta-analysis.
    Shehab A; Bhagavathula AS; Abebe TB; Abegaz TM; Elnour AA; Sabbour HM; Uzzafer M; Hersi A; Hamad AK
    Curr Vasc Pharmacol; 2019; 17(4):341-349. PubMed ID: 29359674
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The treatment pattern and adherence to direct oral anticoagulants in patients with atrial fibrillation aged over 65.
    Han S; Jeong HS; Kim H; Suh HS
    PLoS One; 2019; 14(4):e0214666. PubMed ID: 30934004
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives.
    Ferguson C; Inglis SC; Newton PJ; Middleton S; Macdonald PS; Davidson PM
    J Clin Nurs; 2017 Dec; 26(23-24):4325-4334. PubMed ID: 28178370
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Best practice for atrial fibrillation patient education.
    Lane DA; Barker RV; Lip GY
    Curr Pharm Des; 2015; 21(5):533-43. PubMed ID: 25175094
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Insights Into Direct Oral Anticoagulant Therapy Implementation of Stroke Survivors with Atrial Fibrillation in an Ambulatory Setting.
    Albert V; Polymeris AA; Dietrich F; Engelter ST; Hersberger KE; Schaedelin S; Lyrer PA; Arnet I
    J Stroke Cerebrovasc Dis; 2021 Feb; 30(2):105530. PubMed ID: 33333334
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Shared decision-making in atrial fibrillation: navigating complex issues in partnership with the patient.
    Noseworthy PA; Brito JP; Kunneman M; Hargraves IG; Zeballos-Palacios C; Montori VM; Ting HH
    J Interv Card Electrophysiol; 2019 Nov; 56(2):159-163. PubMed ID: 30327992
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.
    Zhu J; Alexander GC; Nazarian S; Segal JB; Wu AW
    Pharmacotherapy; 2018 Sep; 38(9):907-920. PubMed ID: 29920705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.